NCT06026995

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Clinical Study on the Effectiveness and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells for Lymphoma and Multiple Myeloma

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 174 (estimated)
• Sponsor: Chongqing University Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized controlled, open and multi-center clinical study. Patients who meet the selection criteria and do not meet the exclusion criteria are randomly given PEG-rhG-CSF with a fixed dose of 12mg when white blood cells reach the lowest point, or given rhG-CSF with a daily mobilization of 5-10μ g/kg until the collection is completed, so as to evaluate the effectiveness and safety of PEG-rhG-CSF in mobilizing autologous stem cells for lymphoma and multiple myeloma.

Conditions

• Lymphoma

Interventions

Type	Name	Description
DRUG	PEG-rhG-CSF	Subcutaneous injection with a fixed dose of 12 mg
DRUG	RhG-CSF	Inject rhG-CSF 5-10 μg/kg subcutaneously every day

Timeline

• Start date: 2022-03-01
• Primary completion: 2024-01-01
• Completion: 2024-06-01
• First posted: 2023-09-07
• Last updated: 2023-09-07

Locations

1 site across 1 country: China